Table 3. Associations between clinicopathologic characteristics and DLX4 protein expression (percent positivity).
| Clinicopathologic Characteristics | |||
|---|---|---|---|
| Low n (%) |
High n (%) |
P-value | |
| Number of cases | 3 (10.3) | 26 (89.7) | |
| Age (median) | 57.0 | 59.8 | 0.389a |
| Estrogen receptor | |||
| Positive | 2 (10.0) | 18 (90.0) | >0.999 |
| Negative | 1 (11.1) | 8 (88.9) | |
| Progesterone receptor | |||
| Positive | 2 (16.7) | 10 (83.3) | 0.553 |
| Negative | 1 (5.9) | 16 (94.1) | |
| HER2 | |||
| Positive | 1 (16.7) | 5 (83.3) | 0.515 |
| Negative | 2 (8.7) | 21 (91.3) | |
| Triple negative status | |||
| Positive | 1 (25.0) | 3 (75.0) | 0.371 |
| Negative | 2 (8.0) | 23 (92.0) | |
*In all 29 cases of IBC tissues, associations between hormone-receptors or HER2 status and DLX4 expression (IHC) have been analyzed. It includes ER, PR, HER2 and TNBC. IHC scores were defined in the materials and methods section. For the analysis of the protein expression (IHC), a percentage score of 3 or 4 was considered high, and the score of 0, 1 or 2 low. All of the p-value results except a were obtained from Fisher's exact test. The p-value result of a were from Mann–Whitney U test. *p < 0.05, IBC = inflammatory breast cancer; HER2 = human epidermal growth factor receptor type 2.